Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Abcam Plc (ABCZY)

Abcam Plc (ABCZY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 3,468,559
  • Shares Outstanding, K 205,080
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta 1.36
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.07 (0.40%)
  • Most Recent Dividend 0.035 on 03/19/20
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.5925 +8.47%
on 05/01/20
18.1900 -7.02%
on 05/22/20
+1.0982 (+6.94%)
since 04/27/20
3-Month
11.2600 +50.21%
on 03/16/20
18.1900 -7.02%
on 05/22/20
+2.1332 (+14.43%)
since 02/27/20
52-Week
11.2600 +50.21%
on 03/16/20
19.3800 -12.73%
on 12/16/19
-0.7368 (-4.17%)
since 05/24/19

Most Recent Stories

More News
The global tissue imaging market was valued to be $14.42 billion in 2019 and is anticipated to witness an impressive double-digit growth rate, to reach $37.44 billion by 2030

, /PRNewswire/ -- • Application – Disease Research (Cardiology, Neurology, Oncology, Immunology, Infectious Diseases, Others)• Diagnosis Research- (Cardiology, Neurology, Oncology, Immunology, Infectious...

ABT : 90.76 (+1.43%)
ABCZY : 16.9132 (-4.50%)
A : 86.18 (+0.06%)
FLDM : 4.52 (-3.62%)
MKKGY : 22.3200 (-0.98%)
NINOY : 9.6400 (+3.77%)
OCPNY : 16.5100 (-2.13%)
PKI : 100.02 (+2.61%)
SHMZF : 25.5000 (+4.08%)
The Global Apoptosis Assays Market is expected to grow from USD 3,525.46 Million in 2018 to USD 6,410.34 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 8.91%

Reportlinker.com announces the release of the report "Global Apoptosis Assays Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025" -...

ABCZY : 16.9132 (-4.50%)
MKKGY : 22.3200 (-0.98%)
When Does Market Timing Actually Work? - March 16, 2020

In the long-run, does consistent market timing really matter to be a successful investor?

RDNT : 18.41 (+3.66%)
ABMD : 207.76 (-0.63%)
CSBR : 9.48 (-0.21%)
CMD : 41.17 (+11.36%)
ABCZY : 16.9132 (-4.50%)
Abcam Expands Cell Engineering Capabilities Through Asset Purchase of Applied StemCell's Gene Editing Platform and Oncology Product Portfolio

Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell, Inc. (ASC)...

ABCZY : 16.9132 (-4.50%)
Abcam Announces Successful Acquisition of Expedeon's Proteomics and Immunology Business, Enhancing Its Conjugation Capability

Abcam plc, a global innovator in life science reagents and tools, is pleased to announce the successful completion of the acquisition of Expedeon's Proteomics and Immunology business, which includes Innova...

ABCZY : 16.9132 (-4.50%)
Abcam and BrickBio announce a partnership to incorporate conjugation-ready sites into recombinant antibodies across Abcam's portfolio

Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce a strategic partnership with BrickBio, experts in site-specific protein modification and a Tiger Gene portfolio...

ABCZY : 16.9132 (-4.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ABCZY with:

Key Turning Points

2nd Resistance Point 17.6956
1st Resistance Point 17.3044
Last Price 16.9132
1st Support Level 16.7176
2nd Support Level 16.5220

See More

52-Week High 19.3800
Last Price 16.9132
Fibonacci 61.8% 16.2782
Fibonacci 50% 15.3200
Fibonacci 38.2% 14.3618
52-Week Low 11.2600

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar